Financial Snapshot

Revenue
$57.06M
TTM
Gross Margin
32.54%
TTM
Net Earnings
-$41.50M
TTM
Current Assets
$54.62M
Q2 2023
Current Liabilities
$10.77M
Q2 2023
Current Ratio
507.05%
Q2 2023
Total Assets
$67.78M
Q2 2023
Total Liabilities
$35.76M
Q2 2023
Book Value
$32.03M
Q2 2023
Cash
$26.18M
Q2 2023
P/E
-0.4290
Sep 14, 2023 EST
Free Cash Flow
-$45.46M
TTM

Revenues

Revenues

Revenue YoY Change

Revenues

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Interest Expenses

Interest Expenses To Operating Income %

No data

Other Expense/Income

Interest & Other Expense/Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

No data

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

No data

Treasury Stock Shares

No data

Stock Issuance & Repurchase

Ownership Data

Concept 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Dividends

No data

Stock Price

Market Cap: $17.803 Million

About Conformis Inc

ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. The company is headquartered in Billerica, Massachusetts and currently employs 295 full-time employees. The company went IPO on 2015-07-01. The firm is engaged in the development, manufacturing, and sales of patient-specific products and instrumentation that are individually sized and shaped to fit each patient's various knee and hip anatomy. The firm offers knee replacement products and knee replacement products. The firm's product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant Platinum Services Program, as well as data-informed, standardized solutions that combine many benefits of personalization with an off-the-shelf system. Its sterile, just-in-time, Surgery-in-a-Box delivery system is available with all of its implants and personalized, single-use instruments. The firm owns or in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

Industry: Orthopedic, Prosthetic & Surgical Appliances & Supplies Peers: ABBOTT LABORATORIES Microbot Medical Inc. INVACARE HOLDINGS Corp IRIDEX CORP Nemaura Medical Inc. SCIENTIFIC INDUSTRIES INC Talis Biomedical Corp VAPOTHERM INC